Below is an abstract that appeared in the Journal of the American medical Association. I assume it was written by the USPSTF, but I can’t sure. Regardless, I’d be careful about taking advice from anyone who has trouble realizing only women get pregnant. I certainly would want my pregnant wife, daughter, etc to be cared for by such a physician. Note how the woke writers of this screed forget themselves and let women back into the text. Staying woke require constant vigilance. I’ve added the underlinings. Of course, ethnic differences are attributed to structural racism.
Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality US Preventive Services Task Force Recommendation Statement
Importance Preeclampsia is one of the most serious health problems that affect pregnant persons
Objective To update its 2014 recommendation, the USPSTF commissioned a systematic review to evaluate the effectiveness of low-dose aspirin use to prevent preeclampsia.
Population pregnant persons at high risk for preeclampsia who have no prior adverse effects with or contraindications to low-dose aspirin.
Evidence Assessment The USPSTF concludes with moderate certainty that there is a substantial net benefit of daily low-dose aspirin use to reduce the risk for preeclampsia, preterm birth, small for gestational age/intrauterine growth restriction, and perinatal mortality in pregnant persons at high risk for preeclampsia.
Recommendation The USPSTF recommends the use of low-dose aspirin (81 mg/d) as preventive medication for preeclampsia after 12 weeks of gestation in persons who are at high risk for preeclampsia.
Summary of Recommendation Preeclampsia is one of the most serious health problems that affect pregnant persons. It is a multisystem inflammatory syndrome that is often progressive but has an unclear etiology. Worldwide, preeclampsia is the second most common cause of maternal morbidity and mortality. It is a complication in approximately 4% of pregnancies in the US and contributes to both maternal and infant morbidity and mortality.1 Preeclampsia also accounts for 6% of preterm births and 19% of medically indicated preterm births in the US.1
There are racial and ethnic disparities in the prevalence of and mortality from preeclampsia. non-Hispanic Black women are at greater risk for developing preeclampsia than other women and experience higher rates of maternal and infant morbidity and perinatal mortality than other racial and ethnic groups. In the US, the rate of maternal death from preeclampsia is higher among non-Hispanic Black women than non-Hispanic White women.1,2 Disparities in risk factors for preeclampsia, access to early prenatal care, and obstetric interventions may account for some of the differences in prevalence and clinical outcomes.1 These disparities largely result from historical and current manifestations of structural racism that influence environmental exposures, access to health resources, and overall health status.1,3,4
Recognition of Risk Status Persons with a history of preeclampsia in a previous pregnancy, type 1 or type 2 diabetes, and chronic hypertension are at highest risk for preeclampsia. Additional conditions that place a person at high risk for preeclampsia include multifetal gestation, conception using assisted reproductive technology, autoimmune disease, and kidney disease. Other factors associated with increased preeclampsia risk include nulliparity, high prepregnancy body mass index, family history of preeclampsia, and advanced maternal age (35 years or older). In addition, Black persons have higher rates of preeclampsia and are at increased risk for serious complications due to various societal and health inequities (Table 1).1–3USPSTF Assessment of Magnitude of Net Benefit
The US Preventive Services Task Force (USPSTF) concludes with moderate certainty that there is a substantial net benefit of daily low-dose aspirin use to reduce the risk for preeclampsia, preterm birth, small for gestational age/intrauterine growth restriction, and perinatal mortality in pregnant persons at high risk for preeclampsia.
JAMA. 2021;326(12):1186-1191. doi:10.1001/jama.2021.14781